NASDAQ:SYBX - Synlogic Stock Price, Forecast & News

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Shares of Synlogic reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

Synlogic Inc (NASDAQ:SYBX) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.09. The biotechnology company earned $0.31 million during the quarter, compared to the consensus estimate of $0.46 million. Synlogic had a negative return on equity of 34.49% and a negative net margin of 4,574.82%. View Synlogic's Earnings History.

Synlogic is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Synlogic.

7 brokers have issued 1-year price objectives for Synlogic's shares. Their forecasts range from $2.00 to $25.00. On average, they anticipate Synlogic's share price to reach $14.17 in the next twelve months. This suggests a possible upside of 490.3% from the stock's current price. View Analyst Price Targets for Synlogic.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synlogic.

News articles about SYBX stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Synlogic earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Synlogic.

Synlogic saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,520,000 shares, an increase of 7.8% from the January 15th total of 1,410,000 shares. Based on an average trading volume of 474,400 shares, the days-to-cover ratio is presently 3.2 days. Currently, 8.6% of the shares of the company are sold short. View Synlogic's Current Options Chain.

Some companies that are related to Synlogic include Lexicon Pharmaceuticals (LXRX), AMAG Pharmaceuticals (AMAG), MannKind (MNKD), Kamada (KMDA), OptiNose (OPTN), Wave Life Sciences (WVE), IVERIC bio (ISEE), VBI Vaccines (VBIV), Aduro BioTech (ADRO), MediciNova (MNOV), Kalvista Pharmaceuticals (KALV), Avadel Pharmaceuticals (AVDL), Evofem Biosciences (EVFM), Osmotica Pharmaceuticals (OSMT) and Bicycle Therapeutics (BCYC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO) and Progenics Pharmaceuticals (PGNX).

Synlogic's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.93%), State Street Corp (0.92%), Bank of New York Mellon Corp (0.39%), Jacobs Levy Equity Management Inc. (0.31%), Oxford Asset Management LLP (0.24%) and Goldman Sachs Group Inc. (0.10%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea. View Institutional Ownership Trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. View Insider Buying and Selling for Synlogic.

SYBX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, Bank of New York Mellon Corp, Virtu Financial LLC, Connor Clark & Lunn Investment Management Ltd., Goldman Sachs Group Inc. and UBS Group AG. View Insider Buying and Selling for Synlogic.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYBX stock can currently be purchased for approximately $2.40.

Synlogic has a market capitalization of $77.50 million and generates $2.52 million in revenue each year. The biotechnology company earns $-48,440,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Synlogic employs 74 workers across the globe.View Additional Information About Synlogic.

The official website for Synlogic is http://www.synlogictx.com/.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]